Acrivon Therapeutics, Inc. – SEC Filing Summary

This SEC filing details a transaction by Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, Inc. On May 18, 2026, Ms. Peterson acquired 14,227 shares of Common Stock. This acquisition is related to restricted stock units (RSUs), as indicated by footnote F1. The shares were acquired at a price of $0.0 per share, with a post-transaction total of 18,134 shares. The transaction code used is "A", signifying acquisition. The filing is made on Form 4, with a reporting period ending May 18, 2026, and the signature date on May 20, 2026. The shares acquired represent contingent rights to receive Common Stock, with vesting scheduled to begin on November 18, 2026.